Hepatobiliary Cancer Coverage from Every Angle

Richard S. Finn, MD, on LEAP-002 Trial Findings on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma: Clinical Implications

Posted: Friday, September 30, 2022

Richard S. Finn, MD, of the University of California, Los Angeles Geffen School of Medicine, discusses clinical implications of phase III findings from the LEAP-002 study of lenvatinib plus pembrolizumab vs lenvatinib as first-line therapy for patients with advanced hepatocellular carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.